Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL306033 | 0.90 | SLC6A2 (0.53) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Acetic Acid SCHEMBL15865238 | 0.90 | SLC6A2 (0.53) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL11141085 | 0.80 | SLC6A2 (0.56) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL3747687 | 0.80 | CALM1 (0.52) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL925449 | 0.79 | CYP1A2 (0.52) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL5200141 | 0.78 | SMN1; SMN2 (0.48) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL2778837 | 0.78 | SMN1; SMN2 (0.48) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL8098084 | 0.78 | TAAR1 (0.58) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL135743 | 0.78 | TAAR1 (0.58) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL19011137 | 0.77 | HIF1A (0.57) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281119-A1 | PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2023-11-29 | — | — | EP | claimed |
| US-20230112958-A1 | Smart Drug Delivery System and Pharmaceutical Kit for Dual Nuclear Medical Cytotoxic Theranostics | SCV-SPEZIALCHEMIKALIENVERTRIEB GMBH (DE) | 2023-04-13 | — | — | US | claimed |
| EP-4076534-A1 | SMART DRUG DELIVERY SYSTEM AND PHARMACEUTICAL KIT FOR DUAL NUCLEAR MEDICAL CYTOTOXIC THERANOSTICS | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2022-10-26 | — | — | EP | claimed |
| WO-2022157277-A1 | PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER | SCV - SpezialChemikalienVertrieb GmbH (DE) | 2022-07-28 | — | — | WO | claimed |
| WO-2021123013-A1 | SMART DRUG DELIVERY SYSTEM AND PHARMACEUTICAL KIT FOR DUAL NUCLEAR MEDICAL CYTOTOXIC THERANOSTICS | Johannes Gutenberg-Universität Mainz (DE) | 2021-06-24 | — | — | WO | claimed |
| CN-107106711-B | Conjugated bisphosphonates for diagnosis and treatment of bone disease | SCV公司 | 2021-06-18 | — | — | CN | claimed |
| EP-3206720-B1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2020-04-22 | — | — | EP | claimed |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2017-11-16 | — | — | US | claimed |
| CN-107106711-A | Conjugation diphosphonate for diagnosing and treating osteopathy | SCV公司 | 2017-08-29 | — | — | CN | claimed |
| EP-3206720-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GmbH (DE) | 2017-08-23 | — | — | EP | claimed |
| WO-2016058704-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2016-04-21 | — | — | WO | claimed |
| EP-0442962-B1 | LIPOSOMAL RADIOLOGIC CONTRAST AGENTS | UNGER EVAN C (US) | 1994-01-05 | — | — | EP | claimed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIV ANTWERPEN (BE) | 2025-11-06 | — | — | US | disclosed |
| EP-4531932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Universiteit Antwerpen (BE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025037000-A1 | NOVEL FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND MEDICAL USES THEREOF | UNIVERSITEIT ANTWERPEN (BE) | 2025-02-20 | — | — | WO | disclosed |
| WO-2016058704-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
| EP-0670695-A4 | POLYMERS AS CONTRAST MEDIA FOR MAGNETIC RESONANCE IMAGING. | UNGER EVAN C (US) | 1995-12-13 | — | — | EP | disclosed |
| EP-0670695-A1 | POLYMERS AS CONTRAST MEDIA FOR MAGNETIC RESONANCE IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994008509-A1 | POLYMERS AS CONTRAST MEDIA FOR MAGNETIC RESONANCE IMAGING | UNGER EVAN C (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112958-A1 | Smart Drug Delivery System and Pharmaceutical Kit for Dual Nuclear Medical Cytotoxic Theranostics | CTSS, CTSV, TK1 | TAAR1 755/4885SLC6A2 1216/4885SMN1; SMN2 2089/4885 |
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FIBP, FGF1, FGFR1 | TAAR1 4522/4885SLC6A2 3386/4885SMN1; SMN2 3205/4885 |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | PTH1R, VDR, MEN1 | TAAR1 1528/4885SLC6A2 1242/4885SMN1; SMN2 1879/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | TAAR1 4688/4885SLC6A2 3421/4885SMN1; SMN2 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.